(R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2
中文名称 | (R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2 |
---|---|
中文同义词 | (R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2-苯基乙酸酯;(R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2;FESOTERODINE L-MANDELATE;弗斯特罗定扁桃酸盐;化合物 T11275;非索罗定扁桃酸盐 |
英文名称 | Fesoterodine ((S)-2-hydroxy-2-phenylacetic acid) |
英文同义词 | Fesoterodine ((S)-2-hydroxy-2-phenylacetic acid);2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxy-methylphenyl isobutyrate mandelate;Fesoterodine L-mandelate;Fesoterodine L mandelate,Fesoterodine Lmandelate |
CAS号 | 1206695-46-6 |
分子式 | C34H45NO6 |
分子量 | 563.74 |
EINECS号 | |
相关类别 | |
Mol文件 | 1206695-46-6.mol |
结构式 |
(R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2 性质
储存条件 | Store at -20°C |
---|---|
溶解度 | 溶于二甲基亚砜 |
形态 | 固体 |
颜色 | 白色至米白色 |
pKi: 8.0 (M1), 7.7 (M2), 7.4 (M3), 7.3 (M4) and 7.5 (M5)
Fesoterodine L-mandelate decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition.
After oral administration, Fesoterodine L-mandelate is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine).
Fesoterodine L-mandelate (0.01-1 mg/kg; IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg.
Animal Model: | Bladders from female Sprague-Dawley rats (225-275 g) |
Dosage: | 0.01, 0.1 and 1 mg/kg |
Administration: | IV |
Result: | Reduced the micturition pressure and increased bladder capacity and ICIs at the lowest dose tested of 0.01 mg/kg. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-70053A | Fesoterodine L-mandelate | 5 mg | 600元 | |
2024/08/19 | HY-70053A | (R)-2-(3-(二异丙基氨基)-1-苯基丙基)-4-(羟基甲基)苯基异丁酸酯(S)-2-羟基-2 Fesoterodine L-mandelate | 1206695-46-6 | 10mM * 1mLin DMSO | 744元 |